Canada and US Travel Vaccination Demand Surges as International Tourism Fuels Global Market Growth

United States and Canada are emerging as major centres of demand for travel-related vaccinations as international tourism, overseas education and business travel strengthen the global preventive healthcare industry. The travel vaccines market 2030 forecast from The Business Research Company projects that worldwide sales could reach US$6.46 billion by the end of the decade, supported by an estimated annual growth rate of 7%. North America is expected to remain the largest regional market, with growing interest in pre-travel medical consultations and disease prevention. The findings highlight how international mobility is creating opportunities for vaccine manufacturers, healthcare providers and specialist travel clinics.

Global Travel Vaccines Market 2030 Forecast Reveals Significant Industry Expansion

The global travel vaccines industry is expected to experience sustained expansion through 2030, according to market research published by The Business Research Company on 27 October 2026. The commercial forecast estimates that the sector could reach US$6.46 billion by 2030, reflecting growing demand for immunisation services among international tourists, business professionals, students and people undertaking extended overseas assignments.

The report identifies increasing awareness of infectious disease prevention, improved access to healthcare services and expanding international mobility as important contributors to market growth. Travel vaccination services are also becoming more accessible through pharmacies, private clinics and occupational healthcare providers. However, the projected market value represents a commercial estimate rather than confirmed future revenue or an official government forecast. Actual growth will depend on international travel patterns, vaccination recommendations, product availability and healthcare expenditure.

North America Travel Vaccination Industry Prepares for Strong Growth Through 2030

North America is projected to remain the largest regional market for travel vaccines, increasing from approximately US$1.5 billion in 2025 to US$2.1 billion by 2030. The United States is expected to account for much of this activity, with its national market forecast to expand from approximately US$1.4 billion to US$1.9 billion over the same period.

The research attributes this growth to international travel demand, greater awareness of disease prevention and expanding access to immunisation services. American and Canadian travellers increasingly have access to specialist travel clinics, pharmacy-based vaccination programmes and occupational health services that support preparation for overseas journeys.

Business travel and international education are also relevant because frequent travellers may require destination-specific medical advice. Nevertheless, vaccination requirements vary considerably, and the market’s projected growth should not be interpreted as evidence that every international journey requires additional immunisation.

Hepatitis A and Yellow Fever Vaccines Remain Important to International Travel Health

Hepatitis A vaccination represents an important segment of the travel immunisation industry because the infection can spread through contaminated food and water. The Business Research Company identifies growing demand among tourists, expatriates, humanitarian workers and people travelling to destinations where exposure risks may be higher.

The research also highlights vaccines associated with yellow fever, typhoid, hepatitis B, rabies and meningococcal disease. These products support different preventive healthcare needs, depending on the destination, itinerary and traveller’s circumstances. Some countries require proof of yellow fever vaccination for particular arrivals, while other vaccines may be recommended following an individual medical assessment.

The commercial announcement estimates that hepatitis A vaccines could represent a substantial share of future market demand. However, its stated segment value and percentage share do not fully reconcile, meaning the precise proportion should not be presented as a verified market statistic without clarification.

International Tourism and Business Travel Create New Opportunities for Preventive Healthcare

The expansion of international tourism is creating additional opportunities for travel healthcare providers, particularly as visitors explore destinations with different infectious disease risks. Travellers undertaking multi-country holidays may encounter varying vaccination recommendations, while business professionals attending overseas conferences often need medical preparation within limited timeframes.

The meetings, incentives, conferences and exhibitions sector is another potential contributor to demand. International delegates frequently travel between major commercial centres, making reliable pre-departure health information an important part of corporate travel planning. Educational exchanges, humanitarian assignments and adventure tourism also create demand for specialist consultations.

However, vaccination decisions should reflect individual circumstances rather than general assumptions about particular countries. Healthcare professionals consider medical history, destination-specific risks, planned activities and the duration of travel before recommending immunisation. This approach helps travellers obtain appropriate protection without unnecessary medical procedures.

Asia, Africa and Latin America Highlight the Importance of Destination-Specific Vaccination Advice

International travellers visiting parts of Asia, Africa and Latin America may encounter infectious disease risks requiring additional medical preparation. However, these risks vary substantially between countries and regions, making broad geographical generalisations unreliable.

Some destinations require yellow fever vaccination certificates from travellers arriving from countries with recognised transmission risks. Hepatitis A and typhoid vaccines may be recommended for certain itineraries involving potential exposure through food and water. Rabies pre-exposure vaccination may also be considered for travellers visiting remote areas or undertaking activities involving increased animal contact.

Visitors planning nature-based holidays, extended backpacking trips or humanitarian assignments should consult qualified healthcare professionals before departure. Official guidance from the World Health Organization and national public health authorities can help identify relevant risks and vaccination requirements. Travellers should also review transit-country rules because some entry requirements depend on previous travel history.

Travel Clinics and Digital Healthcare Platforms Prepare for Growing International Demand

The travel vaccination industry is increasingly incorporating digital healthcare services to improve appointment scheduling, medical consultations and immunisation record management. Online booking systems and electronic health records can help travellers organise vaccinations before departure, particularly when preparing for complex international itineraries.

The Business Research Company identifies digital decision-support tools as another potential area of development. These systems may assist healthcare professionals in reviewing destination-specific recommendations and identifying appropriate vaccination schedules. Improvements in vaccine distribution and temperature-controlled supply chains could also support access to immunisation services in underserved markets.

Nevertheless, digital platforms cannot replace professional medical assessment when travellers have complex health histories, contraindications or special vaccination requirements. The sector’s long-term development will depend on maintaining clinical standards alongside technological improvements.

Major Vaccine Manufacturers Target Opportunities in the Expanding Travel Health Market

The commercial research identifies several pharmaceutical companies participating in the wider travel vaccination industry, including Sanofi, GSK, Pfizer, Merck, Takeda, Bavarian Nordic, CSL, Valneva, Bharat Biotech and the Serum Institute of India.

According to the report, Sanofi held an estimated 5% share of global travel vaccine sales in 2025, making it the largest individual participant identified in the announcement. However, this estimate should be understood as a research-based market assessment rather than an independently audited figure.

Manufacturers are developing products, strengthening distribution networks and investing in vaccine research to respond to changing healthcare needs. Future commercial opportunities will depend on regulatory approvals, public health recommendations, affordability and access to healthcare services.

International Travellers Must Review Vaccination Requirements Before Departure

The US Centers for Disease Control and Prevention recommends reviewing routine immunisations and destination-specific health guidance before international travel. Vaccines covering measles, mumps, rubella, tetanus and other preventable diseases may be relevant depending on the traveller’s age and medical history. Additional vaccinations, including hepatitis A, typhoid or yellow fever, may be recommended for selected destinations.

Travellers should ideally arrange a medical consultation four to six weeks before departure because some vaccinations require multiple doses or time to develop protection. However, even last-minute consultations can provide useful guidance.

Certain countries require an International Certificate of Vaccination or Prophylaxis for yellow fever. Under international health regulations, the certificate generally becomes valid ten days after primary vaccination and remains valid for life. Travellers should confirm requirements through official government sources before booking.

Travel Vaccines Market 2030 Highlights a Promising Future for Global Tourism Healthcare

The projected expansion of the travel vaccines market to US$6.46 billion by 2030 highlights the growing relationship between international mobility and preventive healthcare. As families explore new destinations, students pursue overseas education and professionals attend international events, access to reliable medical guidance will remain essential. North America’s expected market leadership reflects substantial commercial opportunities, while vaccine manufacturers and healthcare providers prepare for changing demand. However, successful industry growth will depend on affordability, regulatory standards and evidence-based recommendations. For travellers, the central message remains straightforward: appropriate medical preparation can support safer, more confident international journeys without creating unnecessary concern.

The post Canada and US Travel Vaccination Demand Surges as International Tourism Fuels Global Market Growth appeared first on Travel and Tour World